# Moderna, Inc. Common Stock (MRNA) stock analysis and sentiment Canonical page: https://synoptiv.com/stock/MRNA Methodology: https://synoptiv.com/methodology Author: Synoptiv Research Engine Last analyzed: Aug 24, 2026 Moderna, Inc. Common Stock (MRNA) last closed at $145.13, in the upper half of its 52-week range of $22.28–$176.66. Composite market sentiment across 1 analysis is neutral (+5 on a −100 to +100 scale), as of Aug 24, 2026. ## What the data says Moderna trades at $145.13, closer to the upper end of a 52-week band that runs from $22.28 to $176.66 — a range in which the high is roughly eight times the low. That spread is unusually wide for a company of this size and tells you the stock has repriced dramatically over the past year rather than drifting; the current level sits well above the lows but still meaningfully below the peak. At a market capitalization of about $58 billion, the market is valuing the business on something other than current earnings. Forward P/E is negative at roughly -31.7, and the profit margin of about -141% shows the company is spending far more than it takes in, with revenue growth of roughly 2% over the period measured. Price-to-book near 8.6 puts the valuation at a large multiple of the accounting value of its assets, which is where the market's assessment is being expressed given the absence of profits. Beta of 0.90 indicates the shares have moved slightly less than the broad market on average, though that figure sits oddly against a year in which the price traveled the range described above. Recent coverage is a mix of company-specific and sector-wide items. The company-specific news centers on clinical progress — reporting that Moderna and Merck produced the first mRNA cancer vaccine to succeed in a Phase 3 trial, alongside a story on a sharp single-day move in the stock on August 20 and a late-July piece noting the shares had risen nearly 90% year to date. The remainder of the flow is broader healthcare and biotech: a global influenza vaccine market report listing Moderna among more than a dozen players, and several items about Tempus AI and Ionis that reflect sector attention rather than developments at this company. ## About Moderna, Inc. Common Stock Moderna is a biotechnology company based in Cambridge, Massachusetts, that develops medicines and vaccines based on messenger RNA (mRNA). Founded in 2010 as Moderna Therapeutics and renamed Moderna in 2018, it sells its products in the United States, Europe, and other markets. Its commercial portfolio centers on respiratory vaccines, including Spikevax and mNEXSPIKE for COVID-19 and mRESVIA for respiratory syncytial virus. Beyond respiratory disease, the company's pipeline spans vaccines for latent viruses such as cytomegalovirus, Epstein-Barr virus, and HIV; norovirus and other enteric infections; public health targets including Zika, Nipah, and mpox; and bacterial diseases such as Lyme disease. It also pursues oncology programs, among them individualized cancer therapies and T-cell engagers, and treatments for rare diseases including propionic acidemia, methylmalonic acidemia, and cystic fibrosis. Moderna works through alliances with partners including Merck, Vertex Pharmaceuticals, Immatics, U.S. government agencies such as DARPA and BARDA, and the Bill & Melinda Gates Foundation. ## Company profile - Symbol: MRNA - Exchange: NASDAQ - Security type: Stock - Sector: Healthcare - Industry: Biotechnology - Composite sentiment: neutral (5 on a -100 to +100 scale) ## Key statistics | Metric | Value | | --- | ---: | | Market capitalization | $57.94B | | Enterprise value | $54.09B | | Forward P/E | -31.69 | | Price to book | 8.56 | | Price to sales | 26.01 | | Beta | 0.9 | | Net margin | -1.41% | | Revenue growth | 2.10% | | 52-week high | $176.66 | | 52-week low | $22.28 | | Average volume | 12.88M | ## Related stocks - [AMGN](https://synoptiv.com/stock/AMGN) - [GILD](https://synoptiv.com/stock/GILD) - [VRTX](https://synoptiv.com/stock/VRTX) - [REGN](https://synoptiv.com/stock/REGN) - 950200.KQ - [NTRA](https://synoptiv.com/stock/NTRA) - [RVMD](https://synoptiv.com/stock/RVMD) - [BIIB](https://synoptiv.com/stock/BIIB) - [ALNY](https://synoptiv.com/stock/ALNY) - [INSM](https://synoptiv.com/stock/INSM) - [INCY](https://synoptiv.com/stock/INCY) - 950160.KQ ## Recent news - [Hype for Moderna's Cancer Vaccine Is Running Ahead of the Math](https://www.wsj.com/health/pharma/hype-for-modernas-cancer-vaccine-is-running-ahead-of-the-math-b9b596f5?mod=wsj_FV) — Aug 24, 2026 - [Why Tempus AI Skyrocketed This Week](https://www.fool.com/investing/2026/08/23/why-tempus-ai-skyrocketed-this-week/?source=iedfolrf0000001) — Aug 23, 2026 - [Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math](https://www.wsj.com/health/pharma/hype-for-modernas-cancer-vaccine-is-running-ahead-of-the-math-b9b596f5?siteid=yhoof2&yptr=yahoo) — Aug 23, 2026 - [Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth Story](https://finance.yahoo.com/healthcare/articles/moderna-mrna-soars-179-melanoma-062319268.html) — Aug 23, 2026 - [2 Biotech Stocks Shaping Up for Major Breakouts](https://www.marketbeat.com/articles/2-biotech-stocks-shaping-up-for-major-breakouts/?utm_source=yahoofinance&utm_medium=yahoofinance) — Aug 22, 2026 - [A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know](https://www.fool.com/coverage/filings/2026/08/22/a-tempus-ai-director-sold-stock-four-days-before-a-24-rally-here-s-what-to-know/?source=iedfolrf0000001) — Aug 22, 2026 - [Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade](https://www.fool.com/coverage/filings/2026/08/22/is-tempus-ai-stock-a-buy-after-its-75-rally-here-s-what-to-know-as-the-firm-s-legal-chief-files-a-trade/?source=iedfolrf0000001) — Aug 22, 2026 - [Breakfast News: A Conversation With Ionis CEO](https://www.fool.com/investing/breakfast-news/2026/08/22/breakfast-news/?source=iedfolrf0000001) — Aug 22, 2026 - [MarketBeat Week in Review – 08/17 - 08/21](https://www.marketbeat.com/articles/marketbeat-week-in-review-08-17-08-21/?utm_source=yahoofinance&utm_medium=yahoofinance) — Aug 22, 2026 - [Investors Thought Moderna Was Left for Dead. Then Came a Cancer Breakthrough.](https://www.wsj.com/articles/investors-thought-moderna-was-left-for-dead-then-came-a-cancer-breakthrough-464255d3?siteid=yhoof2&yptr=yahoo) — Aug 22, 2026 ## Frequently asked questions ### What is the current market sentiment for MRNA? As of Aug 24, 2026, Moderna, Inc. Common Stock (MRNA) carries neutral (+5 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report. ### How has MRNA stock been performing? Moderna, Inc. Common Stock last closed at $145.13, in the upper half of its 52-week range of $22.28–$176.66. ### What is MRNA's market cap and valuation? Moderna, Inc. Common Stock has a market capitalization of about $57.94B. ### What sector is MRNA in, and who are its competitors? Moderna, Inc. Common Stock operates in the Healthcare sector, specifically Biotechnology. Comparable companies include AMGN, GILD, VRTX, REGN, 950200.KQ. ### Where can I find a full analysis of MRNA? The full MRNA report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account. ## Important information This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice. - [Methodology](https://synoptiv.com/methodology) - [Disclosures](https://synoptiv.com/disclosures) - [Full report](https://synoptiv.com/stock/MRNA/v/1) (account and access required)